Corcept Therapeutics Incorporated (CORT) is a publicly traded company in the Healthcare — Medical - Pharmaceuticals industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily.
Analysis Summary
Corcept Therapeutics Incorporated reported revenue of $761.4M in the most recent fiscal year, growing at a 5-year CAGR of 16.6%. Net income reached $99.7M, with a -1.2% 5-year CAGR.
Trailing-twelve-month margins: gross margin 98.3%, operating margin 0.8%, net margin 6.6%. Free cash flow grew at -1.2% CAGR over 5 years.
At the current price of $110.29, CORT trades at a P/E of 215.02 and an ROE of 8.37%. Market capitalisation stands at $11.9B, placing it among large-cap names.
Balance sheet quality for CORT: current ratio of 2.9, net cash position of $366.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $141.8M represents 142% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $110.29 |
| Market Cap | $11.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 215.02 |
| Price / Book | 16.69 |
| EV / EBITDA | 421.53 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 8.37% |
| Return on Invested Capital | 0.87% |
| Return on Assets | 6.18% |
| Gross Margin | 98.30% |
| Operating Margin | 0.77% |
| Net Margin | 6.61% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 2.86 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 14.11 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CORT | Corcept Therapeutics Incorporated | $12.4B | 215.02 | 16.69 | 8.4% |
| JAZZ | Jazz Pharmaceuticals plc | $15.3B | 15.68 | 3.14 | 21.4% |
| AXSM | Axsome Therapeutics, Inc. | $10.9B | 132.47 | -255.6% | |
| ABVX | Abivax S.A. | $8.7B | 14.31 | -165.2% | |
| HALO | Halozyme Therapeutics, Inc. | $13.0B | 30.94 | 88.99 | |
| CYTK | Cytokinetics, Incorporated | $8.7B | 119.0% | ||
| NUVL | Nuvalent, Inc. | $9.1B | 8.30 | -42.8% | |
| CAI | Caris Life Sciences, Inc. | $7.1B | 83.14 | 14.78 | 18.8% |
Price Performance
| 1 month | -7.33% |
| 3 months | +38.02% |
| Year-to-date | +216.93% |
| 1 year | +38.21% |
| 3 years | +234.52% |
52-Week Range
| 52-week High | $126.38 |
| 52-week Low | $28.66 |
| Avg Volume (90d) | 1.3M |
Related companies: ABVX · AXSM · CAI · CYTK · HALO · JAZZ · MRUS
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of CORT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks